Introduction 1
Dengue virus (DENV) is a mosquito-borne virus responsible for an estimated 390 2 million annual infections in the tropical and sub-tropical world (Bhatt et al., 2013) . The 3 virus exists as four antigenically distinct serotypes (DENV1-4). Infection with DENV 4 results in a wide spectrum of disease manifestations ranging from mild to life-5 threatening conditions, the latter being characterized by vascular leakage with or 6 without hemorrhage development (World Health Organisation, 2009, Kyle and Harris, 7 2008 ). DENV serotype cross-reactive immunity has been proposed, and to a certain 8 extent demonstrated, to represent a risk for the development of severe dengue. 9
Specifically, pre-existing antibodies raised during a previous heterotypic DENV 10 infection that recognize the structural components of the virion could enhance DENV 11 uptake and facilitate its replication within FcγR-bearing cells, leading to increased 12 disease severity, a phenomenon coined as antibody-dependent enhancement (ADE) 13 (Halstead et al., 2002 , Halstead, 2003 . There is currently no effective therapeutics or 14 vaccine against dengue, which mainly stems from our lack of understanding of dengue 15 pathogenesis associated with limited availability of relevant symptomatic animal 16 models (Yauch and Shresta, 2008, Chan et al., 2015) . The only licensed vaccine 17 Dengvaxia, which consists of chimeric live attenuated tetravalent DENV, not only 18 offers limited protective efficacy particularly towards DENV2 strains, but was also 19 found to predispose immunologically dengue naïve individuals to an increased risk of 20 developing severe disease (Capeding et al., 2014, Villar et al., 2015 , Aguiar et al., 2016 , 21 Halstead, 2017 . This latter observation had led to the suspension of dengue vaccination 22 programmes in the Philippines (Fatima and Syed, 2018) . Thus, safer and more effective 23 second-generation vaccines are urgently needed. In the wake of Dengvaxia setback 24 and controversy, sub-unit vaccine candidates have regained some traction (Lam et al., 25 1 vaccine candidate, a number of studies have also proposed DENV non-structural 2 protein 1 (NS1) as a potential candidate (Schlesinger et al., 1987 , Henchal et al., 1988 DENV infection in a mouse model (Beatty et al., 2015) . These findings thus support 20 that NS1 represents a promising sub-unit vaccine candidate and a safer alternative to 21 avoid the risk of ADE, which is a major roadblock in the development of vaccines that 22 rely on protective immunity against the structural components of DENV. However, the 23 role of NS1 in dengue pathogenesis and the in vivo protective efficacy of NS1 immunity 24 had been demonstrated in mouse models that either produce mild symptoms such as 25 local skin hemorrhage and prolonged bleeding time (Wan et al., 2014 , Wan et al., 2017 , 1 Lai et al., 2017 or employ mouse-adapted DENV2 strains (Schlesinger et al., 1987 , 2 Henchal et al., 1988 , Falgout et al., 1990 , Costa et al., 2006 , Beatty et al., 2015 . 3
Here, the role of NS1 in dengue pathogenesis as well as the protective potential of NS1 4 immunity were investigated in symptomatic dengue mouse models established with a 5 non mouse-adapted DENV2 strain, namely D2Y98P (Tan et al., 2010 , Ng et al., 2014 Martinez Gomez et al., 2016). In these models, neutralization of circulating sNS1 7 through antibody transfer or active NS1 immunization did not confer protection against 8 D2Y98P-induced disease, thus suggesting a limited role of sNS1 in the pathogenesis of 9 D2Y98P. Similar observations were made with a DENV2 clinical isolate that currently 10 circulates in Singapore and Malaysia. Instead, we showed that the prME region drives 11 the in vivo virulence of D2Y98P virus, through induction of key pro-inflammatory 12 cytokines. 13
Results 1

No protective efficacy of NS1 immunity in A129 and AG129 ADE mouse models 2
The protective efficacy of NS1 was evaluated in symptomatic mouse models of dengue 3 that have been established with the non-mouse-adapted DENV2 D2Y98P strain ( representative of DENV2 strains that circulate in Singapore (Table S1) . included. OVA-and NS1-immunized mice were then administered with DENV1-20 immune serum one day prior to infection with D2Y98P strain in order to produce lethal 21 infection in an ADE setting ( Fig. 1A ). 22 NS1 (16681) and NS1 (D2Y98P) share 97% amino acid identity and ability of the 23 immune serum raised against NS1(16681) to bind to and neutralize NS1(D2Y98P) was 24 verified by ELISA and sandwich ELISA, respectively ( Fig. S1B and S1D). Consistently, 25 significant reduction in circulating sNS1 was observed in NS1-immunized mice 1 compared to OVA-immunized animals after viral challenge ( Fig. 1B) , indicating that 2 NS1(16681) immunization successfully neutralized circulating sNS1 produced during 3 infection with D2Y98P virus. However, comparable viremia titers were measured 4 between NS1-immunized mice and OVA controls (Fig. 1C ). Furthermore, NS1-and 5 OVA-immunized mice displayed similar disease manifestations and progression, 6
including hunched back, diarrhoea, lethargy, and eventually all the animals from both 7 groups were moribund by day 4 post-infection (p.i.) ( Fig. 1D and E). Vascular leakage 8 in the liver and small intestines from NS1-immunized animals was as extensive as that 9 measured in the OVA control group (Fig. 1F ). Systemic level of the liver enzyme AST 10 was also comparable between NS1-and OVA-immunized groups ( pathway, direct immunization with purified NS1 may result in sub-optimal immune 23 responses that may affect the protective potential of NS1 immunity (van den Broek et 24 al., 1995). To address this possibility, NS1 immune serum was instead generated in 25 A129 mice according to the same immunization protocol described above. One day 1 prior to DENV2 infection, AG129 mice born to DENV1-immune dams were then 2 passively transferred with the NS1 immune serum ( Fig. 2A) , which led to effective 3 neutralization of circulating sNS1 after D2Y98P challenge ( Fig. 2B ). However, 4 comparable viremia titers ( Fig. 2C ), survival rate ( Fig. 2D ), clinical symptoms ( Fig. 2E ) 5 and vascular leakage ( Fig. 2F ) were observed between mice administered with NS1 6 immune serum and the control group transferred with naïve serum. 7
Together, our data indicate that neither active NS1 immunization nor passive transfer 8 of NS1 immune serum conferred significant protection in both A129 and AG129 ADE 9 models, despite effective neutralization of circulating sNS1. These observations thus 10 imply that in these ADE infection models, sNS1 does not play a critical role in dengue 11 pathogenesis. 12 13
Lack of protective NS1 immunity is independent of mouse background 14
Previous studies that reported NS1-mediated protection were conducted in mouse 15 strains such as IFNAR -/- ( 2017), both being in the C57BL/6 background. We thus questioned whether the 17 discrepancy between our observations and these earlier studies could be explained by a 18 difference in mouse background. Hence, IFNAR -/mice of C56BL/6 background were 19 immunized with NS1 or OVA according to the same immunization regimen as above, 20 followed by lethal challenge with D2Y98P ( Fig. 3A ). NS1-immunized IFNAR -/mice 21 had significantly reduced sNS1 levels after D2Y98P challenge compared to OVA-22 immunized controls, indicating effective neutralization of sNS1 in circulation ( Fig. 3B ). immunized and OVA control groups. These data thus indicate that the lack of protection 1 mediated by NS1-immunity is likely independent of the mouse background. While D2Y98P is not mouse-adapted, the virus had been passaged in C6/36 cell line 6 for several rounds, during which some mutations in the viral genome may have 7 modified the virus fitness. In particular, the presence of a phenylalanine (F) at position 8 52 in NS4B was found to play an important role in D2Y98P in vivo and in vitro fitness 9 (Grant et al., 2011 , Tan et al., 2010 . As none of the other DENV2 strains whose 10 genome sequence is available in the public database, harbors an F at this position, we 11
proposed that this particular amino acid was likely acquired during in vitro passages. 12
To examine whether the findings made with D2Y98P can be extended to other DENV2 13 strains, we have used another DENV2 clinical isolate, EHIE2862Y15, which has been 14 passaged in C6/36 cell line for no more than four rounds. This virus belongs to the 15 cosmopolitan genotype clade Ib that has been circulating in Singapore and Malaysia 16 since 2013 and has been associated with high fatality rate (Ng et al., 2015) . 17 EHIE2862Y15 shares 98.6% nucleotide identity and 99.6% amino acid identity with 18 D2Y98P (Table S2 ). Interestingly, although EHIE2862Y15 does not harbor an F at 19 position 52 in NS4B, infection with EHIE2862Y15 gave rise to symptomatic infection 20 in AG129 mice, with a disease kinetic profile similar to that of D2Y98P ( Fig. S2 ). 21
To evaluate the role of NS1 in the context of EHIE2862Y15 infection, IFNAR -/mice 22
were immunized with purified NS1 followed by lethal viral challenge. Despite the 23 effective neutralization of circulating sNS1 (Fig. 4A ), mice were not protected from 24 lethal EHIE2862Y15 challenge, as evidenced by comparable viremia titers ( Fig. 4B ), 25 survival rates ( Fig. 4C ) and weight loss profile ( Fig. 4D ). Furthermore, significant 1 vascular leakage was measured in the liver and kidneys from NS1-and OVA-2 immunized mice compared to uninfected controls, although the extent of vascular 3 leakage in the liver of NS1-immunized mice was slightly but significantly lower than 4 in OVA-immunized animals ( Fig. 4E ). Overall, these data support that the lack of NS1 5 immunity-mediated protection is not restricted to D2Y98P strain, but also applies to a 6 clinically relevant DENV2 isolate that is circulating in Singapore. 7 8
Exogenous administration of sNS1 did not worsen dengue disease severity 9
To assess the pathogenic role of sNS1 during D2Y98P infection, we tested whether the 10 exogenous administration of purified sNS1(D2Y98P) could aggravate disease severity 11 in AG129 mice infected with a sub-lethal dose of D2Y98P ( Fig. 5A ). Administration 12 of purified sNS1(D2Y98P) at day 2 p.i. led to significantly higher sNS1 level measured 13 at day 4 p.i. compared to mice administered with OVA ( Fig. 5B ). No significant 14 vascular leakage however was detected in any of the infected mice from both groups at 15 this time point ( Fig. 5C ). Vascular leakage was also measured at day 6 p.i., when 16 comparable levels of sNS1 were measured in both groups (Fig. 5B ). It is likely that at 17 this later time point, the sNS1 level mainly results from virus replication, and that 18 exogenously added sNS1 had been cleared from the circulation and/or deposited onto 19 the endothelial layer and internalized by endothelial cells. While no significant vascular 20 leakage was observed in the small intestine and spleen from both infected groups, liver 21 and kidneys did display significant vascular leak compared to uninfected controls ( Fig.  22 5D). However, the extent of vascular leakage was not greater in mice administered with 23 exogenous sNS1 compared to the OVA control group (Fig. 5D ). 24
Since vascular leakage is more prominent at day 6 p.i. in this sub-lethal AG129 model, 1
we reasoned that delaying the exogenous administration of sNS1 from day 2 p.i. to day 2 4 p.i. may have a greater impact on vascular leakage. Significantly higher circulating 3 sNS1 levels were measured at day 6 p.i. in mice administered with purified sNS1 (Fig.  4 5E). However, these mice failed to exhibit greater vascular leakage than the OVA 5 control group (Fig. 5F ). Viremia titers were also not enhanced with sNS1 administration 6 ( However, D2Y98P-infected mice administered with exogenous sNS1 did not display 11 significantly higher levels of TNF-α compared to OVA controls ( Fig. 5G ). Likewise, 12 the levels of heparan sulphate in circulation, indicative of glycocalyx degradation, were 13 not enhanced with NS1 administration (Fig. 5H ). These findings are consistent with the 14 observation that exogenous administration of sNS1 did not increase vascular leakage in 15 D2Y98P-infected mice. 16 17
In vivo virulence of D2Y98P is driven by structural prME region 18
The data described above supported that NS1 does not play a critical role in the 19 pathogenesis and in vivo fitness of the two DENV2 strains employed, and that other 20 viral determinants are involved. The in vivo fitness of DENV was reported to be linked 21 to its organ and cell tropism, which is mainly mediated by the prME structural region 22 that harbors the receptor-binding site (Modis et al., 2004 , Prestwood et al., 2008 . To 23 explore the mechanisms involved in D2Y98P fitness and virulence, we generated a 24 chimeric virus where the prME region from D2Y98P was swapped with that of a 25 DENV1 strain -05K3903DK1, which typically gives rise to asymptomatic transient 1 viremia in AG129 mice ( Fig. 6G ). We also engineered another chimeric virus where 2 NS1 from D2Y98P was replaced by that of DENV1 ( Fig. 6A and B ). 3
Mice infected with DENV1-NS1-D2Y98P displayed a survival profile, clinical 4 manifestations and disease progression that were comparable to those seen with WT 5 D2Y98P virus ( Fig. 6C, E) . On the other hand, mice infected with DENV1-prME-6 D2Y98P remained asymptomatic throughout the experiment, similar to WT DENV1 7 ( Fig. 6D, F) . Interestingly, the peak viremia titer (day 3 p.i.) in mice infected with 8 DENV1-prME-D2Y98P was similar to that measured in mice infected with DENV1-9 NS1-D2Y98P ( Fig. 6G ), although the infection outcome induced by both viruses 10 differed drastically. Together, these observations support that prME, but not NS1, 11 drives D2Y98P virulence in mice. Swapping either NS1 or prME from DENV1 into 12 D2Y98P did impact significantly the viremia titers ( Fig 6G) , suggesting that these 13 proteins play a role in viral replication. The role of NS1 in DENV replication has indeed 14 been well established (Fan et al., 2014) . Furthermore, a previous work has also reported 15 the existence of specific interactions between NS1 and prM/E that facilitate membrane 16 budding or conformational changes in the structural proteins necessary for formation 17 of nucleocapsids (Scaturro et al., 2015) . This suggests that some compatibility between 18 both proteins is required for optimal viral replication. Consistently, when comparing 19 the kinetic profile in Vero cells of D2Y98P with that of DENV1-NS1-D2Y98P, a mild 20 but significant defect could be observed with the chimeric strain ( Fig. 6H ). In contrast, 21 the in vitro kinetic profile of DENV1-prME-D2Y98P was super-imposable to that of 22 WT D2Y98P (Fig. 6I ). This latter observation thus implied that the lower viremia titers 23 measured in mice infected with DENV1-prME-D2Y98P cannot be explained by an 24 intrinsic defect in viral replication. 25
To further understand the basis of the prME-driven virulence of D2Y98P, we examined 1 the cytokine profile in mice infected with the chimeric and WT strains ( Fig 6J and S4 ). 2
Comparable high levels of key pro-inflammatory cytokines TNF-α and IL-6 were 3 measured in mice infected with DENV1-NS1-D2Y98P and WT D2Y98P (Fig. 6J ). On 4 the other hand, mice infected with DENV1-prME-D2Y98P displayed significantly 5 reduced levels of these pro-inflammatory cytokines compared to D2Y98P-infected 6 mice, although higher than the levels measured in DENV1-infected animals ( Fig. 6J) . 7
Furthermore, DENV1-prME-D2Y98P was unable to suppress the production of anti-8 inflammatory IL-10 ( Fig. 6J ). 9
Therefore, our data suggest that the in vivo virulence of D2Y98P virus is mainly driven 10 by its structural component -prME -through its ability to induce the production of key 11 pro-inflammatory cytokines. 12
Discussion 1
The mechanisms that drive the fitness and virulence of DENV remain largely unknown 2 and are likely to be multifactorial. They include the ability to infect and replicate 3 effectively in various host cells as well as the ability to evade or counteract the host context, and using several symptomatic models in different mouse backgrounds, we did 21 not observe a role for circulating sNS1 in dengue pathogenesis. Neither could we see a 22
protective role for NS1 immunity. Similar observations were made with another 23 DENV2 clinical isolate that currently circulates in Singapore and Malaysia, and that is 24 equally virulent in mice. 25
Consistently, the role of NS1 in human dengue disease has remained controversial. A 1 hospital-based study in dengue patients reported a positive association between 2 circulating sNS1 levels and dengue disease severity, and proposed that levels greater 3 than 600 ng/mL are predictive of severe dengue (Libraty et al., 2002) . However, a closer 4 examination of the data revealed that the correlation was not absolute, where a 5 proportion of patients with self-limiting dengue fever displayed levels of sNS1 above 6 600 ng/mL. Likewise, a subset of patients who developed severe dengue had sNS1 7 levels below the detectable range or considerably lower than 600 ng/mL (Libraty et al., 8 2002) . Furthermore, a more recent prospective study conducted in Vietnam found no 9 association between sNS1 level and severe dengue (Fox et al., 2011) . As these patients 10 were likely to be infected with DENV from different serotypes and strains, the authors 11 suggested that the correlation between sNS1 levels and disease severity may be strain- is likely to impact binding efficacy of the virus to its lectin-type host receptors, thereby 19 influencing cell and organ tropism. In addition to receptor binding, glycans on E protein 20 may also play an important role in shaping the host immune responses, through 21 modulation of the lectin pathway of complement activation, and induction of pro-22
inflammatory cytokines through C-type lectin domain family 5 member A (CLEC5A) 23 receptor activation (Chen et al., 2008). Using a chimerization approach, we showed that 24 swapping prME region from DENV1 into D2Y98P virus did not modify the in vitro 25 viral replication rate but significantly impaired the induction of pro-inflammatory 1 cytokines in vivo, which resulted in asymptomatic disease. We have indeed previously 2 shown that pro-inflammatory cytokines, in particular TNFα, play a critical role in be determined experimentally and is beyond the scope of this study. It is however 8 interesting to note that the prME region from DENV2 Singapore clinical isolate -9 EHIE2862Y15, shares 100% amino acid identity with prME of D2Y98P. 10
11
In conclusion, our work supports that the pathogenic role of sNS1 and consequently the 12 protective efficacy of NS1 immunity are not seen in the context of infection with two 13 DENV2 strains that belong to the cosmopolitan genotype, and whose virulence relies 14 instead on their structural components. Hence, we propose that the pathogenic role of 15 sNS1 is likely to be DENV strain-dependent. Given the highly diverse and vast number with 2% FBS as previously described (Ng et al., 2014) . Harvested culture supernatants 2 containing the virus particles were stored at -80 °C. Virus titers were determined by 3 plaque assay in BHK-21 cells as described below. 4
Virus quantification 5
Virus titer was quantified by plaque assay in BHK-21 cells as previously described (Ng 6 et al., 2014) . Briefly, 40,000 cells/well were seeded in 24-well plates (NUNC) one day 7 before plaque assay. Cell monolayers were then infected with 10-fold serially diluted 8 viral suspensions in RPMI-1640 medium supplemented with 2% FBS. After one hour 9 incubation at 37 °C with CO2, overlay medium (RPMI-1640 medium containing 1% 10 (w/v) carboxymethyl cellulose (CMC) and 2% FBS) was added to each well. After 11 incubation for four (DENV2) or five (DENV1) days at 37 °C with CO2, cells were fixed 12 with 4% paraformaldehyde (Sigma-Aldrich) and stained with 0.05% crystal violet 13 (Sigma-Aldrich). Plaques were counted, adjusted by dilution and expressed as the 14 number of plaque forming unit per milliliter (PFU/mL). 15
Chimeric virus construction and production 16
Fragments from DENV2 (D2Y98P) and DENV1 (05K3903DK1) genomes were 17 obtained by polymerase chain reaction (PCR) amplification or de novo synthesis. 18
Primer sequences used for amplification are listed in Table S3 . PCR was performed 19 using Q5 Hot Start high-fidelity DNA polymerase (New England Biolabs) according 20 to the manufacturer's instructions. All PCR products were purified from agarose gel 21 using QIAquick gel extraction kit (Qiagen) following the manufacturer's instructions. 22 DENV1-NS1-D2Y98P and DENV1-prME-D2Y98P chimeric viruses were constructed 23 using DNA assembly of PCR fragments by Gibson assembly technique as previously 24 described (Siridechadilok et al., 2013) . The pACYC177 plasmid containing CMV 25 promoter, HDV ribozyme and SV40 PA was a kind gift from Prof Ooi Eng Eong, Duke-1 NUS. The vector and viral DNA fragments, were assembled together using Gibson 2 Assembly Master Mix (New England Biolabs) at 50 °C for two hours. The assembly 3 mix (15 µL) was then directly transfected into BHK-21 cells using Lipofectamine-4
2000 transfection reagent (Thermo-Fisher) in Opti-MEM medium (Thermo-Fisher) 5 as described in the manufacturer's protocol. After incubation for four hours at 37 °C 6 with CO2, the medium was changed to MEM medium (GIBCO) supplemented with 7 10% FBS. Culture supernatants containing the virus were collected daily from day one 8 to day five post-transfection and the presence of virus was verified by plaque assay. 9
The chimeric viruses were eventually propagated in C6/36 cell line for two passages. 10
NS1 immunization and mouse infection 11
Five to six week-old A129 mice (129/Sv mice deficient in IFN-α/β receptors) were 12 immunized intraperitoneally (ip) thrice (week 0, 2 and 6) with 20 µg of hexameric NS1 13 from DENV2 16681 strain (The Native Antigen Company) or OVA protein (InvivoGen) 14
adjuvanted with 1 µg of monophosphoryl lipid A (MPLA) (InvivoGen) and 1:1 volume 15 AddaVax (InvivoGen) as described previously (Beatty et al., 2015) . Two weeks after 16 the last administration, A129 mice were challenged with 10 6 PFU DENV2 (D2Y98P) 17
intravenously (iv) one day after iv administration of DENV1-immune serum to trigger 18
ADE. 19
Following the same NS1(16681) immunization regimen in A129 mice, NS1 immune 20 serum was collected two weeks after the third immunization and heat-inactivated at 56 21 °C for 30 minutes before storage at -80 °C. Antibody titers of immune serum were 22 quantified by ELISA. The stored immune sera were subsequently used for passive 23 transfer experiment into AG129 mice (129/Sv mice deficient in IFN-α/β and IFN-γ 24 receptors) born to DENV1-immune mothers. One day post-administration of NS1 25 immune serum (150µL per mouse), these AG129 mice were subcutaneously (sc) 1 challenged with 10 3 PFU of DENV2 (D2Y98P). 2
Five to seven week-old IFNAR -/mice (C57BL/6 deficient in interferon-α/β receptors) 3 were subjected to the same immunization regimen with NS1(16681) or OVA protein 4 as described above, and were challenged sc with 10 5 PFU DENV2 (D2Y98P or 5 EHIE2862Y15) two weeks after the third immunization. 6
Administration of NS1 protein 7
Five to six weeks old AG129 mice were infected sc with 10 3 PFU sub-lethal dose of 8 D2Y98P. Two or four days p.i., 10 mg/kg of purified NS1(D2Y98P) (The Native 9
Antigen Company) or OVA protein (InvivoGen) was administered iv to the infected 10 mice. 11
Primary infection with chimeric viruses 12
Five to six weeks old AG129 mice were sc infected with 10 6 PFU of parental (D2Y98P 13 or DENV1) or chimeric (DENV1-NS1-D2Y98P or DENV1-prME-D2Y98P) viruses. 14
Quantification of vascular leakage 15
Vascular leakage was assessed by Evans blue dye extravasation as previously described 16 (Ng et al., 2014) . Briefly, mice were administered intravenously with 0.5% (w/v) Evans 17 blue dye (Sigma-Aldrich) in PBS adjusted to the weight of mouse (10 µL/gram body 18 weight). Two hours after administration, mice were euthanized and extensively 19 perfused with PBS. Organs (liver, small intestines, spleen and kidneys) were harvested 20 and weighed. Evans blue dye was extracted from the organs by the addition of N,N-21 dimethylformamide (Sigma-Aldrich) (adjusted to 4 mL/g wet tissue) and incubated 22 overnight at 37 °C. Extracted dye was read at 620 nm, and data were expressed as 23 absolute absorbance. 24
Histology analysis 25
Mice were sacrificed at the indicated time point and the liver was harvested and fixed 1 immediately with 4% paraformaldehyde in PBS. Fixed tissues were processed for 2 embedding, sectioning and staining with Haematoxylin and Eosin (H&E) (Department 3 of Pathology, NUS). Slides were viewed under microscope (Leica) and images were 4 captured. 5
Enzyme-link immunosorbent assays 6
Levels of systemic IgG antibodies specific to NS1 protein were quantified via indirect 7 enzyme-link immunosorbent assay (ELISA). Purified NS1 protein from D2Y98P or 8 16681 (10 ng/well) diluted in PBS was coated onto 96-well EIA plates (Corning costar) 9 overnight at 4 °C. Plates were washed thrice with wash buffer (0.05% Tween 20 in 10 PBS) and blocked with reagent diluent (2% BSA in wash buffer) for one hour at 37 °C. 11
Serially diluted serum samples were added to the wells and incubated at 37 °C. Plates 12 were washed thrice before the addition of horseradish peroxidase (HRP)-conjugated 13 anti-mouse IgG (H+L) (Bio-rad, 170-6516) at 1:3,000; anti-mouse IgG1, IgG2a and 14
IgG2b (abcam ab97240, ab97245, ab97250) at 1:10,000. Plates were incubated for one 15 hour at 37 °C. After the final three washes, detection was performed by the addition of We thank Prof Subhash Vasudevan, Duke-NUS and Prof Christiane Ruedl, Nanyang 7
Technological University for the kind gift of mouse monoclonal anti-NS1 antibodies 8 for ELISA. We also thank Prof Ooi Eng Eong, Duke-NUS for sharing his pACYC177 9 plasmid construct for Gibson assembly work. 10 : molecular and  9 structural biology, immunology, role in pathogenesis and application as a 
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Fig. S1. NS1-specific IgG titers in NS1 immune serum. A129 mice were ip immunized thrice with 20 µg NS1(16681) or OVA adjuvanted with MPLA and Addavax at week two, six and eight. NS1-specific IgG antibody titers were measured by ELISA using NS1(16681) (A) or NS1(D2Y98P) (B) as coating antigen. Titers were calculated as the reciprocal of the highest serum dilution with absorbance corresponding to three times the absorbance of blank wells. The dotted line indicates the limit of detection. (C) The percentages of specific IgG subclasses were determined. (D) 5x-diluted NS1 immune serum was co-incubated with 20µg/mL NS1(16681) or NS1(D2Y98) and the amount of free NS1 was measured by sandwich ELISA. 
